SCHEMBL32662675

SCHEMBL32662675

NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(NCC4CCCO4)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 5/20 0.60
▸ UBA6 A0AVT1 1/20 0.60
▸ ATG7 O95352 1/20 0.60
▸ UBA7 P41226 1/20 0.60
▸ NAE1 Q13564 1/20 0.60
▸ UBA3 Q8TBC4 1/20 0.60
▸ SAE1 Q9UBE0 1/20 0.60
▸ ADORA3 P0DMS8 4/20 0.55
▸ TAS1R3 Q7RTX0 1/20 0.53
▸ TAS1R1 Q7RTX1 1/20 0.53
▸ ADORA2A P29274 1/20 0.52
▸ ADORA2B P29275 1/20 0.52
▸ EPRS1 P07814 2/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA4 P22748 1/20 0.51
▸ CA9 Q16790 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32662677 0.89 UBA6 (0.57) ADORA1UBA6ATG7UBA7NAE1
SCHEMBL32661823 0.87 ADORA1 (0.65) ADORA1UBA6ATG7UBA7NAE1
SCHEMBL1798569 0.87 ADORA1 (0.65) ADORA1UBA6ATG7UBA7NAE1
SCHEMBL1796399 0.84 UBA6 (0.61) ADORA1UBA6ATG7UBA7NAE1
SCHEMBL32662178 0.83 ADORA1 (0.85) ADORA1ADORA3TAS1R3TAS1R1ADORA2A
SCHEMBL32662022 0.82 ADORA1 (0.84) ADORA1ADORA3TAS1R3TAS1R1ADORA2A
SCHEMBL32662392 0.82 ADORA1 (0.84) ADORA1ADORA3TAS1R3TAS1R1ADORA2A
SCHEMBL32662091 0.82 ADORA1 (0.84) ADORA1ADORA3TAS1R3TAS1R1ADORA2A
SCHEMBL32662540 0.82 SLC29A1 (0.64) ADORA1UBA6ATG7UBA7NAE1
SCHEMBL1798264 0.82 ADORA1 (0.60) ADORA1UBA6ATG7UBA7NAE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2026-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF NAE1, NEDD8, UBA3 ADORA1 4165/4885UBA6 153/4885ATG7 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback